Specifically, on November 4, 2016, Alexion abruptly cancelled an appearance at the Credit Suisse Healthcare Conference and failed to file its quarterly report by market close within its historical two-day window following an earnings announcement on October 27, 2016.
On this news, Alexion's share price fell from $129.00 per share on November 4, 2016 to a closing price of $120.05 on November 7, 2016—a $8.95 or a 6.9% drop.
Then, on November 9, 2016, Alexion revealed that the delay of its quarterly report was due to an investigation being carried out by the audit and finance committee of its board of directors into whether any of its personnel "engaged in sales practices that were inconsistent with company policies and procedures."
Request more information now by clicking here: www.faruqilaw.com/ALXN. There is no cost or obligation to you.
If you invested in Alexion common stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/ALXN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Alexion's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alexion-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-alexion-pharmaceuticals-inc-to-contact-the-firm-300364295.html
SOURCE Faruqi & Faruqi, LLP